A weekly biotech and pharma roundup that walks through recent clinical trial results, deals and stock moves, with a focus on what the numbers do and do not show. It suits readers who want a quick, opinionated read on industry news alongside links to the related video and podcast.
Website: https://www.biotechblueprint.com
Nava Whiteford's ASeq is a technically informed newsletter covering DNA and protein sequencing, diagnostics, life-science tools and biotech strategy. Issues dissect specific companies and their patents or publications, offering a skeptical, expert view of what is known and unresolved.
Long-form explainers on early-stage biotech aimed at investors, currently a series on cell therapy (CAR-T) for autoimmune disease. It lays out mental models for interpreting trial data, target choice and market viability, with clear disclaimers.
A physician-author's blog analysing biotech and oncology developments, including clinical trial data, drug mechanisms and the implications of AI for medicine. Posts include conflict-of-interest disclosures and give detailed scientific commentary on specific companies and drugs.
Two Natural Cap is a research newsletter that analyses drug development and biotech markets, with recent issues covering gene editing, molecular glue degraders, and PROTAC-style protein degraders. Each issue combines mechanistic explanation with commercial context such as clinical data, competitive landscapes and big pharma deal activity.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
